The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World
Open accessAbstract
Understanding the nuances of AmpC β-lactamase–mediated resistance can be challenging, even for the infectious diseases specialist. AmpC resistance can be classified into 3 categories: (1) inducible chromosomal resistance that emerges in the setting of a β-lactam compound, (2) stable derepression due to mutations in ampC regulatory genes, or (3) the presence of plasmid-mediated ampC genes. This review will mainly focus on inducible AmpC resistance in Enterobacteriaceae. Although several observational studies have explored optimal treatment for AmpC producers, few provide reliable insights into effective management approaches. Heterogeneity within the data and inherent selection bias make inferences on effective β-lactam choices problematic. Most experts agree it is prudent to avoid expanded-spectrum (ie, third-generation) cephalosporins for the treatment of organisms posing the greatest risk of ampC induction, which has best been described in the context of Enterobacter cloacae infections. The role of other broad-spectrum β-lactams and the likelihood of ampC induction by other Enterobacteriaceae are less clear. We will review the mechanisms of resistance and triggers resulting in AmpC expression, the species-specific epidemiology of AmpC production, approaches to the detection of AmpC production, and treatment options for AmpC-producing infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performance standards for antimicrobial susceptibility testing
Weinstein, M. P., & Clinical (2019) · Clinical and Laboratory Standards Institute eBooks · Cited by 4,341
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR
Pérez-Pérez, F. J., & Hanson, N. D. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.6.2153-2162.2002 · Cited by 1,512
Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy
Chow, J. W., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P., Ramphal, R., Wagener, M. M., Miyashiro, D. K., & Yu, V. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-8-585 · Cited by 889
Extended-Spectrum-β-Lactamase, AmpC, and Carbapenemase Issues
Thomson, K. S. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00219-10 · Cited by 356
Jacobs, C., Frère, J.-M., & Normark, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81928-5 · Cited by 331
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods
Livermore, D. M. (1987) · European Journal of Clinical Microbiology · doi:10.1007/bf02013107 · Cited by 210
Choi, S.-H., Lee, J. E., Park, S. J., Choi, S.-H., Lee, S.-O., Jeong, J.-Y., Kim, M.-N., Woo, J. H., & Kim, Y. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-07 · Cited by 190
Regulatory components in Citrobacter freundii ampC beta-lactamase induction.
Lindberg, F., Westman, L., & Normark, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.14.4620 · Cited by 182
Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp
Kaye, K. S., Cosgrove, S., Harris, A., Eliopoulos, G. M., & Carmeli, Y. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2628-2630.2001 · Cited by 181
Honoré, N., Nicolas, M. H., & Cole, S. T. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04704.x · Cited by 180
Epidemiology of Conjugative Plasmid-Mediated AmpC β-Lactamases in the United States
Alvarez, M., Tran, J. H., Chow, N., & Jacoby, G. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.533-537.2004 · Cited by 178
The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
Tamma, P. D., Girdwood, S. C. T., Gopaul, R., Tekle, T., Roberts, A. A., Harris, A. D., Cosgrove, S. E., & Carroll, K. C. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit395 · Cited by 172
Self-citationJacobson, K. L., Cohen, S. H., Inciardi, J. F., King, J. H., Lippert, W. E., Iglesias, T., & VanCouwenberghe, C. J. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1107 · Cited by 165
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Pogue, J. M., Bonomo, R. A., & Kaye, K. S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy576 · Cited by 164
Self-citationStructure-Based Enhancement of Boronic Acid-Based Inhibitors of AmpC β-Lactamase
Weston, G. S., Blázquez, J., Baquero, F., & Shoichet, B. K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980343w · Cited by 142
Efficacy of Cefepime in the Treatment of Infections Due to Multiply Resistant Enterobacter Species
Sanders, W. E., Tenney, J. H., & KESSLER, R. E. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.454 · Cited by 133
Kohlmann, R., Bähr, T., & Gatermann, S. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky084 · Cited by 120
Pfaller, M. A., Jones, R. N., Marshall, S. A., Coffman, S. L., Hollis, R. J., Edmond, M. B., & Wenzel, R. P. (1997) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00064-3 · Cited by 110
Molecular basis of beta-lactamase induction in bacteria
Bennett, P. M., & Chopra, I. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.2.153 · Cited by 109
Hancock, R. E. W., & Bellido, F. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.suppl_a.1 · Cited by 105
Cheng, L., Nelson, B. C., Mehta, M., Seval, N., Park, S. E., Giddins, M. J., Shi, Q., Whittier, S., Gomez‐Simmonds, A., & Uhlemann, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-17 · Cited by 98
Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia
Siedner, M. J., Galar, A., Guzmán‐Suarez, B. B., Kubiak, D. W., Baghdady, N., Ferraro, M. J., Hooper, D. C., O’Brien, T. F., & Marty, F. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu182 · Cited by 97
Model System To Evaluate the Effect of ampD Mutations on AmpC-Mediated β-Lactam Resistance
Schmidtke, A. J., & Hanson, N. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-05 · Cited by 93
Harris, P. N. A., Wei, J. Y., Shen, A., Abdile, A. A., Paynter, S., Huxley, R., Pandeya, N., Doi, Y., Huh, K., O’Neal, C. S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv346 · Cited by 92
Self-citationAkova, M., Yang, Y., & Livermore, D. M. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.2.199 · Cited by 90
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
Tamma, P. D., & Hsu, A. J. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz002 · Cited by 85
Self-citationLee, N., Lee, C., Li, C., Li, M.-C., Chen, P., Chang, C., & Ko, W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-15 · Cited by 83
Diverse potential of beta-lactamase inhibitors to induce class I enzymes
Weber, D. A., & Sanders, C. C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.156 · Cited by 77
Kaneko, K., Okamoto, R., Nakano, R., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.2955-2958.2005 · Cited by 72
Hilty, M., Sendi, P., Seiffert, S. N., Droz, S., Perreten, V., Hujer, A. M., Bonomo, R. A., Mühlemann, K., & Endimiani, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.022 · Cited by 65
Self-citationEndemic Emergence of Cephalosporin-Resistant Enterobacter: Relation to Prior Therapy
Weinstein, R. A. (1986) · Infection Control and Hospital Epidemiology · doi:10.1017/s0195941700065632 · Cited by 64
Fung-Tomc, J. C., Gradelski, E., Huczko, E., Dougherty, T. J., KESSLER, R. E., & BONNER, D. P. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1289 · Cited by 62
Choi, S., Lee, J. E., Park, S. J., Kim, M.-N., Choo, E. J., Kwak, Y. G., Jeong, J.-Y., Woo, J. H., Kim, N. J., & Kim, Y. S. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0308-2 · Cited by 54
Folkesson, A., Eriksson, S., Andersson, M., Park, J. T., & Normark, S. J. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00443.x · Cited by 47
Penicillin-binding proteins and induction of AmpC beta-lactamase
Sanders, C. C., Bradford, P. A., Ehrhardt, A. F., Bush, K., Young, K. D., Henderson, T. A., & Sanders, W. E. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.2013 · Cited by 47
Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia
Marcos, M., Iñurrieta, A., Soriano, À., Martínez, J. A., Almela, M., Marco, F., & Mensa, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn155 · Cited by 44
Antibacterial in vitro activity of fourth generation cephalosporins.
Hancock, R. E. W., & Bellido, F. (1996) · PubMed · Cited by 43
Rapid Emergence of Resistance to Cefepime During Treatment
Limaye, A. P., Gautom, R., Black, D. J., & Fritsche, T. R. (1997) · Clinical Infectious Diseases · doi:10.1086/516917 · Cited by 40
Chaubey, V. P., Pitout, J. D. D., Dalton, B., Gregson, D. B., Ross, T., & Laupland, K. B. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0647-4 · Cited by 38
Black, J. A., Thomson, K. S., Buynak, J. D., & Pitout, J. D. D. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.4168-4171.2005 · Cited by 37
Huh, K., Kang, C., Kim, J., Cho, S. Y., Ha, Y. E., Joo, E., Chung, D. R., Lee, N. Y., Peck, K. R., & Song, J. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.11.002 · Cited by 34
Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula
Johnson, C. C., Livornese, L. L., Gold, M. J., Pitsakis, P. G., Taylor, S., & Levison, M. E. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.6.765 · Cited by 33
Lister, P. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.14.213s.35045 · Cited by 30
Stearne, L. E. T., van Boxtel, D., Lemmens, N., Goessens, W. H. F., Mouton, J. W., & Gyssens, I. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1688-1698.2004 · Cited by 25
Blanchette, L. M., Kuti, J. L., Nicolau, D. P., et al. (2014) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2014.954262 · Cited by 24
Negri, M.-C., & Baquero, F. (1999) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1999.tb00721.x · Cited by 18
Aitken, S. L., Foolad, F., & McDaneld, P. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01160-17 · Cited by 5
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1013 · Cited by 519
Self-citationMultidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Metadata
- Authors
- Tamma, P. D., Doi, Y., Bonomo, R. A., Johnson, J. K., Simner, P. J., Antibacterial Resistance Leadership Group, Tamma, P. D., Doi, Y., & Bonomo, R. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-06
- Volume
- 69
- Issue
- 8
- Pages
- 1446-1455
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2921330592
- Cited by
- 322
- References
- 49
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.